CN116211982B - Compound preparation for treating middle-low-risk pulmonary nodules, preparation method and application - Google Patents
Compound preparation for treating middle-low-risk pulmonary nodules, preparation method and application Download PDFInfo
- Publication number
- CN116211982B CN116211982B CN202310055780.9A CN202310055780A CN116211982B CN 116211982 B CN116211982 B CN 116211982B CN 202310055780 A CN202310055780 A CN 202310055780A CN 116211982 B CN116211982 B CN 116211982B
- Authority
- CN
- China
- Prior art keywords
- parts
- weight
- pulmonary nodules
- compound preparation
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000002685 pulmonary effect Effects 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title claims abstract description 34
- 150000001875 compounds Chemical class 0.000 title claims abstract description 31
- 239000003814 drug Substances 0.000 claims abstract description 55
- 238000011282 treatment Methods 0.000 claims abstract description 17
- 241001522129 Pinellia Species 0.000 claims abstract description 15
- 244000179560 Prunella vulgaris Species 0.000 claims abstract description 15
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 15
- 235000008113 selfheal Nutrition 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 14
- 241001547125 Fritillaria thunbergii Species 0.000 claims abstract description 13
- 210000000582 semen Anatomy 0.000 claims abstract description 7
- 235000014375 Curcuma Nutrition 0.000 claims abstract description 5
- 244000164480 Curcuma aromatica Species 0.000 claims abstract description 5
- 240000009138 Curcuma zedoaria Species 0.000 claims abstract description 5
- 235000003405 Curcuma zedoaria Nutrition 0.000 claims abstract description 5
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 claims abstract description 5
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims abstract description 5
- 235000019509 white turmeric Nutrition 0.000 claims abstract description 5
- 239000007788 liquid Substances 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 241000245665 Taraxacum Species 0.000 claims description 14
- 235000006463 Brassica alba Nutrition 0.000 claims description 6
- 244000140786 Brassica hirta Species 0.000 claims description 6
- 235000011371 Brassica hirta Nutrition 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 238000002791 soaking Methods 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000004072 lung Anatomy 0.000 abstract description 32
- 230000000694 effects Effects 0.000 abstract description 8
- 240000001949 Taraxacum officinale Species 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 19
- 206010062717 Increased upper airway secretion Diseases 0.000 description 12
- 208000026435 phlegm Diseases 0.000 description 12
- 206010056342 Pulmonary mass Diseases 0.000 description 9
- 210000000038 chest Anatomy 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 238000003745 diagnosis Methods 0.000 description 7
- 206010008479 Chest Pain Diseases 0.000 description 6
- 206010011224 Cough Diseases 0.000 description 6
- 239000005337 ground glass Substances 0.000 description 6
- 230000002146 bilateral effect Effects 0.000 description 5
- 230000004087 circulation Effects 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 206010013082 Discomfort Diseases 0.000 description 3
- 206010014561 Emphysema Diseases 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 208000002352 blister Diseases 0.000 description 3
- 210000001370 mediastinum Anatomy 0.000 description 3
- 230000024121 nodulation Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 241000721047 Danaus plexippus Species 0.000 description 2
- 208000006907 Multiple Pulmonary Nodules Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 230000002308 calcification Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 210000003281 pleural cavity Anatomy 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- 241000197194 Bulla Species 0.000 description 1
- 241000935235 Fritillaria meleagris Species 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 244000081426 Ranunculus ficaria Species 0.000 description 1
- 235000002226 Ranunculus ficaria Nutrition 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 208000022532 enlargement of lymph nodes Diseases 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/536—Prunella or Brunella (selfheal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/808—Scrophularia (figwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8966—Fritillaria, e.g. checker lily or mission bells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a compound preparation for treating middle-low risk pulmonary nodules, a preparation method and application thereof, wherein the compound preparation comprises the following components in parts by weight: 12-18 parts of dandelion, 27-30 parts of radix cynanchi wilfordii, 9-12 parts of fritillaria thunbergii, 27-30 parts of raw corrugated, 9-12 parts of prepared pinellia ternate, 9-30 parts of selfheal, 9-12 parts of curcuma zedoary, 9-12 parts of semen brassicae, 12-30 parts of radix scrophulariae and 6-9 parts of fructus aurantii. The traditional Chinese medicine compound preparation takes a lung clearing and detoxifying method as a treatment principle, and has obvious curative effect on patients with low-risk pulmonary nodules.
Description
Technical Field
The invention relates to a traditional Chinese medicine compound preparation, in particular to a compound preparation for treating middle-low risk pulmonary nodules, a preparation method and application thereof.
Background
Pulmonary Nodules (PN) refer to round-like or irregular lesions with a diameter of less than or equal to 30mm in the lung, and are represented by shadows with increased density in imaging, which may be single or multiple lesions with clear or unclear boundaries. The detection rate of lung nodules in chest CT examination of healthy people can reach 35.5%.
Pulmonary nodules are classified as solid pulmonary nodules, ground glass density nodules, and multiple pulmonary nodules. Surgical treatment options are most preferred for high-risk pulmonary solid nodules, pulmonary branch solid nodules, and multiple pulmonary nodules. For low-risk lung nodules, including solid lung nodules with the diameter less than or equal to 8mm, solid lung nodules and ground glass density nodules with the diameter less than 5mm, if no surgical indication exists, a follow-up mode is mostly adopted clinically, the control is not needed, and the surgical treatment is first selected when the growth is found.
However, over time, a significant portion of benign knots at low risk may turn malignant, life threatening, and existing treatment regimens fail to improve the patient's clinical symptoms, lacking effective intervention.
Disclosure of Invention
The invention aims to provide a traditional Chinese medicine compound preparation for treating middle-low risk pulmonary nodules by taking a lung clearing and detoxifying method and a phlegm resolving and mass resolving method as treatment principles.
In order to achieve the aim, the invention provides a compound preparation for treating middle-low risk pulmonary nodules, which comprises the following components in parts by weight: 12-18 parts of dandelion, 27-30 parts of radix cynanchi wilfordii, 9-12 parts of fritillaria thunbergii, 27-30 parts of raw corrugated, 9-12 parts of prepared pinellia ternate, 9-30 parts of selfheal, 9-12 parts of curcuma zedoary, 9-12 parts of semen brassicae, 12-30 parts of radix scrophulariae and 6-9 parts of fructus aurantii.
Optionally, the compound preparation comprises the following components in parts by weight: 14-16 parts of dandelion, 28-30 parts of radix cynanchi wilfordii, 10-11 parts of fritillaria thunbergii, 28-30 parts of raw corrugated, 10-11 parts of prepared pinellia ternate, 20-30 parts of selfheal, 10-11 parts of curcuma zedoary, 10-11 parts of semen brassicae, 14-20 parts of radix scrophulariae and 6-8 parts of fructus aurantii.
Optionally, the compound preparation comprises the following components in parts by weight: 15 parts of dandelion, 30 parts of radix cynanchi, 10 parts of fritillaria thunbergii, 30 parts of raw corrugated, 10 parts of prepared pinellia tuber, 30 parts of selfheal, 10 parts of rhizoma curcumae, 10 parts of white mustard seed, 15 parts of radix scrophulariae and 6 parts of fructus aurantii.
The invention also provides a preparation method of the compound preparation for treating the middle-low risk pulmonary nodules, which comprises the following steps:
step 1, soaking the components for 0.5 to 1 hour;
step 2, adding water until the weight of the water is 2 times of the sum of the weight of the components, decocting for 15-20 minutes, and pouring out to obtain a first liquid medicine;
step 3, adding water again until the weight of the water is 2 times of the sum of the weight of the components, decocting for 30-40 minutes, and pouring out to obtain a second liquid medicine;
and step 4, combining the first liquid medicine and the second liquid medicine to obtain the compound preparation for treating the middle-low risk pulmonary nodules.
Optionally, the method comprises:
step 1, soaking each component for 1 hour;
step 2, adding water until the weight of the water is 2 times of the sum of the weight of the components, decocting for 15 minutes, and pouring out the water to serve as a first liquid medicine;
step 3, adding water again until the weight of the water is 2 times of the sum of the weight of the components, decocting for 30 minutes, and pouring out to obtain a second liquid medicine;
and step 4, combining the first liquid medicine and the second liquid medicine to obtain the compound preparation for treating the middle-low risk pulmonary nodules.
The invention also provides application of the compound preparation for treating the middle-low risk pulmonary nodules in preparing medicines for treating the middle-low risk pulmonary nodules.
The invention has the beneficial effects that:
jin Suowei is bitter and cool, and selfheal is bitter and cold in nature, clear away lung-heat and detoxify, and has the efficacy of dissipating middle-low risk pulmonary nodules; dandelion has sweet taste, clears heat and eliminates stagnation, zhejiang fritillary has bitter taste and cold property, eliminates phlegm and eliminates stagnation, pinellia has pungent taste and can promote qi circulation and eliminate phlegm, and the three medicines together play the roles of eliminating phlegm and eliminating stagnation; the four medicines are combined to soften hardness and remove mass; fructus Aurantii regulates qi and moves stagnancy, guides the medicines.
Detailed Description
The main traditional Chinese medicine treatment methods for treating lung nodules at present comprise the methods of promoting qi circulation and blood circulation, clearing heat and detoxicating, soothing liver and regulating qi, promoting blood circulation and removing blood stasis, promoting qi circulation and soothing liver, and eliminating mass and resolving hard mass. The invention claims to prepare the medicine for treating the middle-low risk pulmonary nodule by taking a lung clearing and detoxifying method and a phlegm resolving and masses resolving method as a principle.
The invention takes the radix cynanchi wilfordii and the selfheal as the monarch drugs, clears away the lung-heat and detoxifies, leaves Jin Suowei bitter and cool, has bitter and cold property of the selfheal, has the efficacy of dissipating middle-low risk pulmonary nodules, contains ferulic acid, and has the anti-tumor effect in modern pharmacology; dandelion, fritillaria thunbergii and pinellia ternate are taken as ministerial drugs, dandelion is sweet and neutral in taste, clear heat and dissipate nodulation, fritillaria thunbergii is bitter and cold in property and is capable of resolving phlegm and resolving nodulation, pinellia ternate is pungent and parallel in taste and qi-moving and resolving phlegm, and the three drugs have the effects of resolving phlegm and resolving nodulation together; the preparation is prepared from raw corrugated, rhizoma curcumae, semen brassicae and radix scrophulariae serving as adjuvant drugs, wherein the raw corrugated is used for softening and resolving hard mass, the rhizoma curcumae is used for promoting qi circulation and removing food retention, the semen brassicae is used for eliminating phlegm and promoting qi circulation, the radix scrophulariae is used for nourishing yin and removing toxicity, and the radix scrophulariae is used for softening and resolving hard mass; fructus Aurantii is used as a guiding drug, and the fructus Aurantii regulates qi and moves stagnancy to guide the drugs.
Example 1
A compound formulation for treating low-risk pulmonary nodules comprising: 12g of dandelion, 27g of radix cynanchi, 9g of fritillaria thunbergii, 27g of raw corrugated, 9g of prepared pinellia tuber, 9g of selfheal, 9g of rhizoma curcumae, 9g of white mustard seed, 12g of radix scrophulariae and 6g of fructus aurantii.
Example 2
A compound formulation for treating low-risk pulmonary nodules comprising: 18g of dandelion, 30g of radix cynanchi, 12g of fritillaria thunbergii, 30g of raw corrugated, 12g of prepared pinellia tuber, 30g of selfheal, 12g of rhizoma curcumae, 12g of white mustard seed, 30g of radix scrophulariae and 9g of fructus aurantii.
Example 3
A compound formulation for treating low-risk pulmonary nodules comprising: 15g of dandelion, 30g of radix cynanchi, 10g of fritillaria thunbergii, 30g of raw corrugated, 10g of prepared pinellia tuber, 30g of selfheal, 10g of rhizoma curcumae, 10g of white mustard seed, 15g of radix scrophulariae and 6g of fructus aurantii.
Example 4
A preparation method of a compound preparation for treating middle-low risk pulmonary nodules comprises the following steps:
step 1, soaking each component in examples 1-3 with water for 1 hour;
step 2, adding water until the weight of the water is 2 times of the sum of the weight of the components, decocting for 15 minutes, and pouring out the water to serve as a first liquid medicine;
step 3, adding water again until the weight of the water is 2 times of the sum of the weight of the components, decocting for 30 minutes, and pouring out to obtain a second liquid medicine;
and step 4, combining the first liquid medicine and the second liquid medicine to obtain the compound preparation for treating the middle-low risk pulmonary nodules.
In the clinical treatment, the effect of the compound preparation for treating the middle-low-risk pulmonary nodules is verified.
1. Case selection and grouping
(1) Case selection: reference is made to the guidelines for classification, diagnosis and treatment of pulmonary nodules in China (2016 edition) formulated by the expert group for early diagnosis and treatment of Chinese lung cancer in 2016.
(1) No obvious signs of malignancy CT; (2) pulmonary solid nodules with the diameter less than or equal to 8mm and pulmonary partial solid nodules with the diameter less than or equal to 8mm; (3) lung-ground glass density nodules.
(2) Case grouping: the treatment groups and the control groups were randomized according to a random table.
(1) Treatment group (administration of the formulation of the invention + follow-up): 29 cases
(2) Control group (follow-up only): 28 cases
The two groups of patients were comparable with no significant differences in age, sex, course of disease and severity of disease (P > 0.05).
2. Method of observation and treatment
(1) The observation method comprises the following steps: the morphology of lung CT lung nodules was observed before and after treatment of group 2.
(2) The treatment method comprises the following steps: the treatment group uses the formula of clearing lung and resolving masses: according to the processing specification of Shanghai city decoction pieces, the medicinal materials of 1995 edition are dandelion, pinellia tuber, figwort root, selfheal and the like. The amounts of the components of example 3 were prepared as provided in example 4. After the first liquid medicine and the second liquid medicine are mixed, the first liquid medicine and the second liquid medicine are separated into bags for encapsulation, and each bag is about 160 ml. 160ml of the medicine is taken twice a day, each time in the morning and evening, and 3 months is a treatment course.
3. Standard of efficacy: reference is made to the guidelines of clinical research on new Chinese medicine.
(1) Clinical recovery: the lung nodules disappeared;
(2) The effect is shown: lung nodules were reduced by more than 60%;
(3) The method is effective: the lung nodule is reduced by 30 to 59 percent;
(4) Invalidation: pulmonary nodules do not change or turn into high risk nodules;
the total effective rate is the sum of healing, obvious effect and effective rate.
4. Therapeutic results and analysis
(1) Treatment group 29: 2 cases of clinical recovery, 10 cases of obvious effects, 11 cases of effective cases and 6 cases of ineffective cases, and the total effective rate is 79.31%;
(2) control 28 cases: 0 cases of clinical recovery, 2 cases of obvious effects, 11 cases of effective cases, 15 cases of ineffective cases, and the total effective rate is 46.42%;
compared with the control group, the total effective rate of the patients in the treatment group is obviously higher than that of the patients in the control group, the difference is obvious, and the statistical significance is achieved (P < 0.05).
Typical cases:
case 1
Zhang, woman, age 46, han nationality. 2020-07 in external chest CT: the left subpulmonary She Weixiao nodule (left subpulmonary lobe with a solid nodule lamina 198 with a major diameter of about 4.8mm; right subpulmonary lobe with a solid nodule lamina 180 with a major diameter of about 4.1mm. Bilateral pleural cavity has no apparent effusion). The doctor can make a doctor before 8 months in 2020, and chest distress and urgent need not be caused during the doctor's doctor, and cough and expectoration are avoided, and other discomforts are avoided. The medicines are decocted for 1 dose in 1 day, and the medicine is orally taken in the morning and evening. 2020-11 chest CT in my hospital: no obvious abnormalities were seen. Chest distress and short breath during the re-diagnosis are not caused, and other discomforts are avoided.
Case 2
Some in summer, men, 65 years old, han nationality. 2021-03 in external chest CT: two lung air bags and lung bulla; the lower right lung is She Xiongmo with tiny ground glass nodules; lower right lung She Weixiao nodule; lower right lung She Gaihua kitchen; the middle lobe and the chordae of the right lung (the texture of the two lungs is deepened, the two lungs see lung air bags and lung large bubbles, the IM25 under the right lung She Xiongmo is a 3mm undersize micro ground glass nodule, the boundary is undersize, the lower right lung lobes IM43 and 48-49 are 4mm uniform micro nodules, the boundary is clearer, the lower right lung lobes see calcification foci, the middle right lung lobes see chordae shadows, the cavities of the bronchi are smooth, the phylum and the mediastinum do not see enlarged lymph nodes, the bilateral pleura does not see obvious thickening, and the bilateral pleural cavity does not see obvious effusion). The diagnosis is carried out 10 months in 2022, and the following steps are: the occasional cough is accompanied by a small amount of white sticky phlegm, has no chest distress and no other discomfort. The medicines are decocted for 1 dose in 1 day, and the medicine is orally taken in the morning and evening. 2021-01 external hospital review chest CT: both lungs are scattered in chronic inflammation and are locally old; two lung powder are scattered in the vesicular emphysema with large lung bleb (two lung powder are scattered in the maize shadow, the chordae shadow and the calcification foci), two lung powder are scattered in the vesicular emphysema with large lung bleb, the visible trachea and bronchus cavity are smooth, the two lung gates and the mediastinum are not obvious enlarged lymph nodes, and no hydrops exists in the chest of the two sides.
Case 3
Wu is a certain, female, 37 years old, han nationality. 2020-12 chest CT: upper right lung She Weixiao nodule (upper right lung leaf IM24 seen with a ground glass micro nodule, long diameter about 3mm. No apparent effusion was seen in bilateral chest). The doctor can make a diagnosis in the 12 months of 2020, and feel occasional force during the diagnosis, and has no chest distress, urgent need, cough and expectoration and other discomfort. The medicines are decocted for 1 dose in 1 day, and the medicine is orally taken in the morning and evening. 2021-03 breast CT: no obvious abnormalities were seen.
Case 4
Mulberry is somewhere, male, 63 years old, han nationality. 2020-10 chest CT: the upper right and lower two-lung lobular nodes (about 4-6mm. Bilateral hilar structure is clear, the morphology, size and location are all obvious abnormalities. No abnormal enlargement of lymph nodes in each group in mediastinum). The doctor can make a diagnosis 11 months before 2020, and cough is obvious at night, cough is white and sticky with phlegm, chest distress is felt, and other discomfort is avoided. The medicines are decocted for 1 dose in 1 day, and the medicine is orally taken in the morning and evening. 2021-03 breast CT: multiple focal small emphysema on upper lobe of two lungs, and pleural promyelocytic range on lower lobe of left lung. The cough and expectoration and chest distress symptoms of the re-diagnosis are not caused, and other discomforts are avoided.
In conclusion, the invention provides a compound preparation for treating middle-low risk pulmonary nodules, which takes radix cynanchi wilfordii and selfheal as monarch drugs to clear away lung heat and detoxify; dandelion, fritillary bulb and pinellia tuber are taken as ministerial drugs for resolving phlegm and resolving masses; takes raw corrugated, rhizoma zedoariae, white mustard seed and radix scrophulariae as adjuvant drugs to soften hardness and eliminate mass; fructus Aurantii is used as guiding drug to guide the drugs. The compound preparation has obvious curative effect on middle-low risk pulmonary nodules.
While the present invention has been described in detail through the foregoing description of the preferred embodiment, it should be understood that the foregoing description is not to be considered as limiting the invention. Many modifications and substitutions of the present invention will become apparent to those of ordinary skill in the art upon reading the foregoing. Accordingly, the scope of the invention should be limited only by the attached claims.
Claims (6)
1. The compound preparation for treating the middle-low risk pulmonary nodules is characterized by comprising the following components in parts by weight: 12-18 parts of dandelion, 27-30 parts of radix cynanchi wilfordii, 9-12 parts of fritillaria thunbergii, 27-30 parts of raw corrugated, 9-12 parts of prepared pinellia ternate, 9-30 parts of selfheal, 9-12 parts of curcuma zedoary, 9-12 parts of semen brassicae, 12-30 parts of radix scrophulariae and 6-9 parts of fructus aurantii.
2. The compound preparation for treating middle-low risk pulmonary nodules of claim 1, which consists of the following components in parts by weight: 14-16 parts of dandelion, 28-30 parts of radix cynanchi wilfordii, 10-11 parts of fritillaria thunbergii, 28-30 parts of raw corrugated, 10-11 parts of prepared pinellia ternate, 20-30 parts of selfheal, 10-11 parts of curcuma zedoary, 10-11 parts of semen brassicae, 14-20 parts of radix scrophulariae and 6-8 parts of fructus aurantii.
3. The compound preparation for treating middle-low risk pulmonary nodules of claim 2, which consists of the following components in parts by weight: 15 parts of dandelion, 30 parts of radix cynanchi, 10 parts of fritillaria thunbergii, 30 parts of raw corrugated, 10 parts of prepared pinellia tuber, 30 parts of selfheal, 10 parts of rhizoma curcumae, 10 parts of white mustard seed, 15 parts of radix scrophulariae and 6 parts of fructus aurantii.
4. A method for preparing a compound preparation for treating low-risk pulmonary nodules according to any one of claims 1 to 3, comprising:
step 1, soaking the components for 0.5 to 1 hour;
step 2, adding water until the weight of the water is 2 times of the sum of the weight of the components, decocting for 15-20 minutes, and pouring out to obtain a first liquid medicine;
step 3, adding water again until the weight of the water is 2 times of the sum of the weight of the components, decocting for 30-40 minutes, and pouring out to obtain a second liquid medicine;
and step 4, combining the first liquid medicine and the second liquid medicine to obtain the compound preparation for treating the middle-low risk pulmonary nodules.
5. The method for preparing the compound preparation for treating the middle-low risk pulmonary nodules according to claim 4, comprising the steps of:
step 1, soaking each component for 1 hour;
step 2, adding water until the weight of the water is 2 times of the sum of the weight of the components, decocting for 15 minutes, and pouring out the water to serve as a first liquid medicine;
step 3, adding water again until the weight of the water is 2 times of the sum of the weight of the components, decocting for 30 minutes, and pouring out to obtain a second liquid medicine;
and step 4, combining the first liquid medicine and the second liquid medicine to obtain the compound preparation for treating the middle-low risk pulmonary nodules.
6. Use of a compound formulation according to any one of claims 1-3 for the treatment of medium-low risk pulmonary nodules in the manufacture of a medicament for the treatment of medium-low risk pulmonary nodules.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310055780.9A CN116211982B (en) | 2023-01-17 | 2023-01-17 | Compound preparation for treating middle-low-risk pulmonary nodules, preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310055780.9A CN116211982B (en) | 2023-01-17 | 2023-01-17 | Compound preparation for treating middle-low-risk pulmonary nodules, preparation method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116211982A CN116211982A (en) | 2023-06-06 |
| CN116211982B true CN116211982B (en) | 2023-12-12 |
Family
ID=86585142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310055780.9A Active CN116211982B (en) | 2023-01-17 | 2023-01-17 | Compound preparation for treating middle-low-risk pulmonary nodules, preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116211982B (en) |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105816806A (en) * | 2016-04-26 | 2016-08-03 | 郑州市中医院 | Traditional Chinese medicine preparation for treating thyroid nodule |
| CN107050375A (en) * | 2016-12-31 | 2017-08-18 | 潍坊医学院 | It is a kind of to treat Chinese medicine of sarcoidosis of lung and preparation method thereof |
| CN107929545A (en) * | 2017-12-19 | 2018-04-20 | 北京昆达中医医学研究院 | A kind of Chinese medicine compound prescription for treating Small pulmonary nodule |
| CN109620866A (en) * | 2018-12-26 | 2019-04-16 | 山东神名生物科技有限公司 | A kind of seaweed thallus laminariae soup for treating thyroid nodule and lymph tubercle |
| CN110433247A (en) * | 2019-09-16 | 2019-11-12 | 北京东方运嘉科技发展有限公司 | A kind of pharmaceutical composition and preparation method thereof for treating Lung neoplasm |
| WO2021227614A1 (en) * | 2020-05-15 | 2021-11-18 | 张莹雯 | Pharmaceutical composition for clearing lung and pulmonary fibrosis and use thereof |
| CN113813359A (en) * | 2021-08-22 | 2021-12-21 | 天津市天大天福生物技术有限公司 | Technology and product preparation for treating migraine, arthralgia, stagnation and inflammation by using antibacterial peptide for dredging channels and collaterals and carrying out transdermal administration on lymph |
| CN114042124A (en) * | 2021-12-01 | 2022-02-15 | 江苏省中医院 | Traditional Chinese medicine preparation for treating pulmonary vitreous nodules and preparation method and application thereof |
| CN114788858A (en) * | 2022-06-09 | 2022-07-26 | 烟台市中医医院 | Traditional Chinese medicine pill for treating nodules as well as preparation method and application thereof |
| CN115252748A (en) * | 2022-09-21 | 2022-11-01 | 云南琼月企业管理有限公司 | Pharmaceutical composition for treating pulmonary nodules and preparation and application thereof |
-
2023
- 2023-01-17 CN CN202310055780.9A patent/CN116211982B/en active Active
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105816806A (en) * | 2016-04-26 | 2016-08-03 | 郑州市中医院 | Traditional Chinese medicine preparation for treating thyroid nodule |
| CN107050375A (en) * | 2016-12-31 | 2017-08-18 | 潍坊医学院 | It is a kind of to treat Chinese medicine of sarcoidosis of lung and preparation method thereof |
| CN107929545A (en) * | 2017-12-19 | 2018-04-20 | 北京昆达中医医学研究院 | A kind of Chinese medicine compound prescription for treating Small pulmonary nodule |
| CN109620866A (en) * | 2018-12-26 | 2019-04-16 | 山东神名生物科技有限公司 | A kind of seaweed thallus laminariae soup for treating thyroid nodule and lymph tubercle |
| CN110433247A (en) * | 2019-09-16 | 2019-11-12 | 北京东方运嘉科技发展有限公司 | A kind of pharmaceutical composition and preparation method thereof for treating Lung neoplasm |
| WO2021227614A1 (en) * | 2020-05-15 | 2021-11-18 | 张莹雯 | Pharmaceutical composition for clearing lung and pulmonary fibrosis and use thereof |
| CN113813359A (en) * | 2021-08-22 | 2021-12-21 | 天津市天大天福生物技术有限公司 | Technology and product preparation for treating migraine, arthralgia, stagnation and inflammation by using antibacterial peptide for dredging channels and collaterals and carrying out transdermal administration on lymph |
| CN114042124A (en) * | 2021-12-01 | 2022-02-15 | 江苏省中医院 | Traditional Chinese medicine preparation for treating pulmonary vitreous nodules and preparation method and application thereof |
| CN114788858A (en) * | 2022-06-09 | 2022-07-26 | 烟台市中医医院 | Traditional Chinese medicine pill for treating nodules as well as preparation method and application thereof |
| CN115252748A (en) * | 2022-09-21 | 2022-11-01 | 云南琼月企业管理有限公司 | Pharmaceutical composition for treating pulmonary nodules and preparation and application thereof |
Non-Patent Citations (5)
| Title |
|---|
| 基于关联规则分析罗玲治疗肺结节组方规律;祝海毅;曹晋;陈勇;王洁;罗玲;任毅;;实用中医内科杂志(第08期);第7-11页 * |
| 小柴胡汤为主治疗结节病6例;沈奋怡;中国中西医结合杂志;-;第-卷(第08期);第493-494页 * |
| 张晓梅结合CT影像辨治肺结节;满君;张晓梅;于小林;刘彧杉;闫宏;;中华中医药杂志(第04期);第246-248页 * |
| 益肺活血化痰散结法治疗187例肺结节临床观察;刘彧杉;张晓梅;姜良铎;董环;于小林;顾潇枫;满君;闫宏;李思敏;崔晋伟;赖宇鑫;;中华中医药杂志(第02期);第498-500页 * |
| 贝牡莪消丸对结节性甲状腺肿患者血清VEGF水平的影响;春燕;马建;杜丽坤;张春玲;;中医药信息;-;第-卷(第04期);第93-94页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116211982A (en) | 2023-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111298048B (en) | Traditional Chinese medicine composition for treating novel coronavirus pneumonia and application thereof | |
| CN114042124B (en) | Traditional Chinese medicine preparation for treating pulmonary vitreous nodules and preparation method and application thereof | |
| CN111388582B (en) | Traditional Chinese medicine composition for treating novel coronavirus pneumonia and application of preparation thereof | |
| WO2021179505A1 (en) | Forsythia suspensa and astragalus membranaceus compound preparation, preparation method therefor and application thereof | |
| CN115252748B (en) | Pharmaceutical composition for treating pulmonary nodules and preparation and application thereof | |
| CN116211982B (en) | Compound preparation for treating middle-low-risk pulmonary nodules, preparation method and application | |
| CN104208473A (en) | Traditional Chinese medicine composition for treating wind-heat type cough and asthma and use thereof | |
| CN114788858B (en) | Traditional Chinese medicine pill for treating nodules as well as preparation method and application thereof | |
| CN104306793B (en) | A kind of Chinese medicine preparation for treating lobar pneumonia | |
| CN105497723A (en) | Traditional Chinese medicine preparation for treating bacterial pneumonia and preparation method thereof | |
| CN105194271A (en) | Traditional Chinese medicine preparation for treating advanced breast cancer by virtue of combined chemotherapy | |
| CN112569310B (en) | Yin-nourishing and oral liquid for treating radioactive xerostomia | |
| CN103860682B (en) | One treats phthisical Chinese medicine preparation and preparation method | |
| CN1131062C (en) | Trachitis treating Chinese medicine | |
| CN104288681A (en) | Traditional Chinese medicine composition for treating children virus pneumonia | |
| CN108272989A (en) | Treat the Chinese medicine composition of lung cancer | |
| CN1281257C (en) | Combination of Chinese herbal medicine for curing chronic tracheitis and chronic bronchitis | |
| CN118557694A (en) | Traditional Chinese medicine composition for treating lung cancer postoperative cough | |
| CN104474286A (en) | Traditional Chinese medicine composite for treating dry-heat lung impairing type chronic bronchitis | |
| CN105031379A (en) | Traditional Chinese medicine preparation used for treating upper respiratory tract infection and preparation method | |
| CN104491369B (en) | Medicinal composition for treating hemoptysis | |
| CN104758907B (en) | A kind of Chinese medicine composition for the treatment of radiation pneumonia | |
| CN104083733A (en) | Traditional Chinese medicine preparation for cold-type children's bronchitis | |
| CN118267446A (en) | Traditional Chinese medicine composition for treating cough caused by cold and preparation method and application thereof | |
| CN117959382A (en) | Traditional Chinese medicine composition for treating pulmonary nodules and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |